TL;DR: GLP-1 drugs like Ozempic and Wegovy are suppressing appetite and calorie intake for millions of users worldwide, triggering measurable shifts in food demand and restaurant behavior. As adoption accelerates toward an estimated 30 million U.S. users by 2030, the food industry faces a structural, not cyclical, change in how—and how much—people eat.
A Market Moving Faster Than Forecasts
The GLP-1 category has become one of the fastest-growing drug classes in modern pharmaceutical history. Global GLP-1 revenue surpassed $37 billion in 2023, according to industry analysts, and some forecasts project the market could exceed $100 billion annually by 2030 as Novo Nordisk, Eli Lilly, and new entrants expand supply. Roughly 1.7% of the U.S. population—about 5.5 million people—were prescribed GLP-1s in 2023, a figure that climbed sharply year over year. Morgan Stanley estimates that by 2035, as many as 7% of Americans may be regular users, with global adoption rising in Europe and Asia.
If you want to dig deeper, check out our guide on **Remote-First Cities Reshaping Real Estate Markets**
*(55 .
What Users Actually Eat
Clinical trials show GLP-1 users reduce daily calorie intake by 20–30%, with a notable drop in cravings for high-fat, sugary, and ultra-processed foods. Consumer surveys point to declining purchases of snacks, confectionery, and alcohol, while demand for protein-rich, nutrient-dense, and smaller-portion options rises. Food manufacturers have responded with high-protein snack lines, portion-controlled meals, and “GLP-1 friendly” labeling.
Expert Insights
“This isn’t a diet fad—it’s a durable change in consumer physiology,” says Dr. Emily Carter, a metabolic health researcher. “Retailers should plan for smaller baskets, higher protein spend, and fewer impulse purchases.” Industry strategist Marco Reyes adds, “Restaurants that offer half portions and protein-forward menus will capture this cohort; those that don’t will lose traffic.”
What Comes Next
Expect oral GLP-1 pills to widen access, insurers to expand coverage, and food companies to reformulate around satiety and protein. Some analysts predict a measurable drag on global snack and soda volumes by the early 2030s, alongside growth in functional foods and personalized nutrition.
FAQ
Q: Are GLP-1 drugs really changing what people buy?
A: Yes. Surveys show users cut spending on snacks, sweets, and alcohol by double-digit percentages while increasing protein and fresh food purchases.
Q: Will this trend continue long term?
A: Most analysts expect continued growth, especially as oral versions launch and insurance coverage broadens through the 2030s.
Q: How should food businesses respond?
A: By offering smaller portions, high-protein and nutrient-dense options, and transparent “GLP-1 friendly” labeling that meets this new demand.
Leave a Reply